787 related articles for article (PubMed ID: 25402363)
1. Eradicating HIV-1 infection: seeking to clear a persistent pathogen.
Archin NM; Sung JM; Garrido C; Soriano-Sarabia N; Margolis DM
Nat Rev Microbiol; 2014 Nov; 12(11):750-64. PubMed ID: 25402363
[TBL] [Abstract][Full Text] [Related]
2. Eradication of HIV-1 latent reservoirs through therapeutic vaccination.
Pankrac J; Klein K; Mann JFS
AIDS Res Ther; 2017 Sep; 14(1):45. PubMed ID: 28893280
[TBL] [Abstract][Full Text] [Related]
3. Reservoirs for HIV-1: mechanisms for viral persistence in the presence of antiviral immune responses and antiretroviral therapy.
Pierson T; McArthur J; Siliciano RF
Annu Rev Immunol; 2000; 18():665-708. PubMed ID: 10837072
[TBL] [Abstract][Full Text] [Related]
4. Establishment of a Novel Humanized Mouse Model To Investigate
Flerin NC; Bardhi A; Zheng JH; Korom M; Folkvord J; Kovacs C; Benko E; Truong R; Mota T; Connick E; Jones RB; Lynch RM; Goldstein H
J Virol; 2019 Mar; 93(6):. PubMed ID: 30626677
[TBL] [Abstract][Full Text] [Related]
5. Attacking the HIV reservoir from the immune and viral perspective.
Massanella M; Martinez-Picado J; Blanco J
Curr HIV/AIDS Rep; 2013 Mar; 10(1):33-41. PubMed ID: 23242702
[TBL] [Abstract][Full Text] [Related]
6. Therapeutic Approaches to Eradicate Latent HIV-1 in Resting CD4+ T Cells.
Sluis-Cremer N
Curr Top Med Chem; 2016; 16(10):1191-7. PubMed ID: 26324046
[TBL] [Abstract][Full Text] [Related]
7. HIV reservoirs: what, where and how to target them.
Churchill MJ; Deeks SG; Margolis DM; Siliciano RF; Swanstrom R
Nat Rev Microbiol; 2016 Jan; 14(1):55-60. PubMed ID: 26616417
[TBL] [Abstract][Full Text] [Related]
8. Modeling latently infected cell activation: viral and latent reservoir persistence, and viral blips in HIV-infected patients on potent therapy.
Rong L; Perelson AS
PLoS Comput Biol; 2009 Oct; 5(10):e1000533. PubMed ID: 19834532
[TBL] [Abstract][Full Text] [Related]
9. The Clonal Expansion Dynamics of the HIV-1 Reservoir: Mechanisms of Integration Site-Dependent Proliferation and HIV-1 Persistence.
Yeh YJ; Yang K; Razmi A; Ho YC
Viruses; 2021 Sep; 13(9):. PubMed ID: 34578439
[TBL] [Abstract][Full Text] [Related]
10. The Potential of the CNS as a Reservoir for HIV-1 Infection: Implications for HIV Eradication.
Fois AF; Brew BJ
Curr HIV/AIDS Rep; 2015 Jun; 12(2):299-303. PubMed ID: 25869939
[TBL] [Abstract][Full Text] [Related]
11. Strategies to eradicate HIV from infected patients: elimination of latent provirus reservoirs.
Sadowski I; Hashemi FB
Cell Mol Life Sci; 2019 Sep; 76(18):3583-3600. PubMed ID: 31129856
[TBL] [Abstract][Full Text] [Related]
12. HIV-1 Latency and Viral Reservoirs: Existing Reversal Approaches and Potential Technologies, Targets, and Pathways Involved in HIV Latency Studies.
Khanal S; Schank M; El Gazzar M; Moorman JP; Yao ZQ
Cells; 2021 Feb; 10(2):. PubMed ID: 33672138
[TBL] [Abstract][Full Text] [Related]
13. The Pathway To Establishing HIV Latency Is Critical to How Latency Is Maintained and Reversed.
Rezaei SD; Lu HK; Chang JJ; Rhodes A; Lewin SR; Cameron PU
J Virol; 2018 Jul; 92(13):. PubMed ID: 29643247
[TBL] [Abstract][Full Text] [Related]
14. VIP-SPOT: an Innovative Assay To Quantify the Productive HIV-1 Reservoir in the Monitoring of Cure Strategies.
Puertas MC; Bayón-Gil Á; Garcia-Guerrero MC; Salgado M; Urrea V; Morón-López S; Peña R; Jiménez-Moyano E; Clotet B; Prado JG; Martinez-Picado J
mBio; 2021 Jun; 12(3):e0056021. PubMed ID: 34154408
[TBL] [Abstract][Full Text] [Related]
15. Latent HIV-1 infection of resting CD4⁺ T cells in the humanized Rag2⁻/⁻ γc⁻/⁻ mouse.
Choudhary SK; Archin NM; Cheema M; Dahl NP; Garcia JV; Margolis DM
J Virol; 2012 Jan; 86(1):114-20. PubMed ID: 22013038
[TBL] [Abstract][Full Text] [Related]
16. Underlying mechanisms of HIV-1 latency.
Romani B; Allahbakhshi E
Virus Genes; 2017 Jun; 53(3):329-339. PubMed ID: 28258391
[TBL] [Abstract][Full Text] [Related]
17. Development of 5' LTR DNA methylation of latent HIV-1 provirus in cell line models and in long-term-infected individuals.
Trejbalová K; Kovářová D; Blažková J; Machala L; Jilich D; Weber J; Kučerová D; Vencálek O; Hirsch I; Hejnar J
Clin Epigenetics; 2016; 8():19. PubMed ID: 26900410
[TBL] [Abstract][Full Text] [Related]
18. Differences in HIV Markers between Infected Individuals Treated with Different ART Regimens: Implications for the Persistence of Viral Reservoirs.
Darcis G; Berkhout B; Pasternak AO
Viruses; 2020 Apr; 12(5):. PubMed ID: 32349381
[TBL] [Abstract][Full Text] [Related]
19. HIV Replication and Latency in a Humanized NSG Mouse Model during Suppressive Oral Combinational Antiretroviral Therapy.
Satheesan S; Li H; Burnett JC; Takahashi M; Li S; Wu SX; Synold TW; Rossi JJ; Zhou J
J Virol; 2018 Apr; 92(7):. PubMed ID: 29343582
[TBL] [Abstract][Full Text] [Related]
20. The development of immune-modulating compounds to disrupt HIV latency.
Remoli AL; Marsili G; Battistini A; Sgarbanti M
Cytokine Growth Factor Rev; 2012; 23(4-5):159-72. PubMed ID: 22766356
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
